BRIEF—Agios Pharmaceuticals appoints new CEO

Agios Pharmaceuticals is to replace its chief executive David Schenkein with current board member Jacqualyn Fouse. Mr Schenkein will become executive chairman of the board of directors.

Dr Fouse has previously served as president and chief operating officer at Celgene, which she joined in 2010 as chief financial officer.

Chairman John Maraganore said the appointment was “the result of a thoughtful succession planning process jointly undertaken by David and the board.”

Agios is looking at using cellular metabolism to treat cancer and rare genetic diseases.